外泌体在乳腺癌诊治中的研究进展

doi:10.3969/j.issn.1673-8640.2020.12.001

检验医学 ›› 2020, Vol. 35 ›› Issue (12): 1203-1206.DOI: 10.3969/j.issn.1673-8640.2020.12.001

• 外泌体在肿瘤诊疗中的应用专题 • 下一篇

外泌体在乳腺癌诊治中的研究进展

梅兆玲¹, 周文辉², 冯景²()

1.安徽理工大学医学院,安徽淮南 232001
2.安徽理工大学附属奉贤医院检验科,上海 201499

收稿日期:2020-10-13 出版日期:2020-12-30 发布日期:2020-12-31
作者简介:null
作者简介：梅兆玲,女,1990年生,硕士,技师,主要从事临床检验工作。
基金资助:
国家自然科学基金面上项目（81672624）;国家自然科学基金面上项目（81772817）;上海市医学领军人才培养计划（2019LJ25）;上海健康医学院协同创新重点专项（SPCI-17-15-001）

The Progress of Exosomes Application in Diagnosis and Treatmeat of breast cancer

MEI Zhaoling¹, ZHOU Wenhui², FENG Jing²()

1. Medical school,Anhui University of Science and Technology,Huainan 232001,China
2. Department of Clinical Laboratory,Anhui University of Science and Technology Affiliated Fengxian Hospital,Shanghai 201499,China

Received:2020-10-13 Online:2020-12-30 Published:2020-12-31

摘要/Abstract

摘要：

外泌体是由大多数细胞产生的脂质双层小囊泡,囊泡内包含丰富的核酸、蛋白质和脂质等物质。外泌体对于乳腺癌等肿瘤的发生、发展具有显著的调控作用。乳腺癌细胞来源的外泌体具有显著的细胞特异性,在乳腺癌的早期诊断中具有重要的应用价值。由于外泌体具有良好的生物相容性、体内循环能力及物质运载能力,因此被广泛用于乳腺癌治疗药物的研究中。文章对外泌体在乳腺癌诊疗中的研究进展进行概述,总结了当前乳腺癌外泌体研究面临的主要问题。

关键词: 外泌体, 微小RNA, 乳腺癌, 靶向治疗

Abstract:

Exosomes are small lipid bilayer vesicles,which contents nucleic acids,proteins,lipids and lots of other things. Exosomes have great potential to regulator the occurrence and development of breast cancer. Exosomes derived from breast cancer cells have great potential in the application of early diagnosis and prognosis of breast cancer. Otherwise,the great biocompatibility,natural circulation ability,and strong loading capacity makes exosomes widely used in the developing of drugs for breast cancer treatment. This article gives a brief overview of its application in diagnosis and treatment of breast cancer,the main problems were summarized.

Key words: Exosome, MicroRNA, Breast cancer, Targeted therapy

中图分类号:

R446.1

梅兆玲, 周文辉, 冯景. 外泌体在乳腺癌诊治中的研究进展[J]. 检验医学, 2020, 35(12): 1203-1206.

MEI Zhaoling, ZHOU Wenhui, FENG Jing. The Progress of Exosomes Application in Diagnosis and Treatmeat of breast cancer[J]. Laboratory Medicine, 2020, 35(12): 1203-1206.

参考文献 35

[1]	SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2020[J]. CA Cancer J Clin,2020,70(1):7-30.
[2]	PONDÉ N F,ZARDAVAS D,PICCART M.Progress in adjuvant systemic therapy for breast cancer[J]. Nat Rev Clin Oncol,2019,16(1):27-44.
[3]	KOWAL J,ARRAS G,COLOMBO M,et al.Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes[J]. Proc Natl Acad Sci U S A,2016,113(8):E968-E977.
[4]	YANG C,ROBBINS P D.The roles of tumor-derived exosomes in cancer pathogenesis[J]. Clin Dev Immunol,2011,2011:842849.
[5]	ZHANG Y,LIU Y,LIU H,et al.Exosomes:biogenesis,biologic function and clinical potential[J]. Cell Biosci,2019,9:19.
[6]	LOWRY M C,GALLAGHER W M,O'DRISCOLL L. The role of exosomes in breast cancer[J]. Clin Chem,2015,61(12):1457-1465.
[7]	CHAPUT N,SCHARTZ N E,ANDRÉ F,et al.Exosomes as potent cell-free peptide-based vaccine. Ⅱ. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection[J]. J Immunol,2004,172(4):2137-2146.
[8]	EWAISHA R,GAWRYLETZ C D,ANDERSON K S.Crucial considerations for pipelines to validate circulating biomarkers for breast cancer[J]. Expert Rev Proteomics,2016,13(2):201-211.
[9]	KLINKE D J znd,KULKARNI Y M,WU Y,et al. Inferring alterations in cell-to-cell communication in HER2+ breast cancer using secretome profiling of three cell models[J]. Biotechnol Bioeng,2014,111(9):1853-1863.
[10]	MENG Y,SUN J,WANG X,et al.Exosomes:a promising avenue for the diagnosis of breast cancer[J]. Technol Cancer Res Treat,2019,18:1533033818821421.
[11]	TYTELL M,LASEK R J,GAINER H.Axonal maintenance,glia,exosomes,and heat shock proteins[J]. F1000Res,2016,5(F1000 Faculty Rev):205.
[12]	SANTOS J C,LIMA N D S,SARIAN L O,et al. Exosome-mediated breast cancer chemoresistance via miR-155 transfer[J]. Sci Rep,2018,8(1):829.
[13]	陈丽娥,谢谢,王识华. 外泌体在乳腺癌病理诊断中的应用进展[J]. 医学综述,2020,26(14):2803-2806.
[14]	罗娇,周莉. 外泌体在乳腺癌脑转移诊断和治疗中的研究进展[J]. 肿瘤,2020,40(5):361-370.
[15]	GAO X,LI S,DING F,et al.Rapid detection of exosomal micrornas using virus-mimicking fusogenic vesicles[J]. Angew Chem Int Ed Engl,2019,58(26):8719-8723.
[16]	ZHANG C,JI Q,YANG Y,et al.Exosome:function and role in cancer metastasis and drug resistance[J]. Technol Cancer Res Treat,2018,17:1533033818763450.
[17]	MASHOURI L,YOUSEFI H,AREF A R,et al.Exosomes:composition,biogenesis,and mechanisms in cancer metastasis and drug resistance[J]. Mol Cancer,2019,18(1):75.
[18]	IM E J,LEE C H,MOON P G,et al.Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A[J]. Nat Commun,2019,10(1):1387.
[19]	XIA X,WANG X,ZHANG S,et al.miR-31 shuttled by halofuginone-induced exosomes suppresses MFC-7 cell proliferation by modulating the HDAC2/cell cycle signaling axis[J]. J Cell Physiol,2019,234(10):18970-18984.
[20]	WEI Y,LI M,CUI S,et al.Shikonin inhibits the proliferation of human breast cancer cells by reducing tumor-derived exosomes[J]. Molecules,2016,21(6):777.
[21]	SHTAM T A,KOVALEV R A,VARFOLOMEEVA E Y,et al.Exosomes are natural carriers of exogenous siRNA to human cells in vitro[J]. Cell Commun Signal,2013,11:88.
[22]	KIM M S,HANEY M J,ZHAO Y,et al.Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells[J]. Nanomedicine,2016,12(3):655-664.
[23]	SATO Y T,UMEZAKI K,SAWADA S,et al.Engineering hybrid exosomes by membrane fusion with liposomes[J]. Sci Rep,2016,6:21933.
[24]	FUHRMANN G,SERIO A,MAZO M,et al.Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins[J]. J Control Release,2015,205:35-44.
[25]	MILANO G,BIEMMI V,LAZZARINI E,et al.Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin/trastuzumab-induced cardiac toxicity[J]. Cardiovasc Res,2020,116(2):383-392.
[26]	KALIMUTHU S,GANGADARAN P,RAJENDRAN R L,et al.A new approach for loading anticancer drugs into mesenchymal stem cell-derived exosome mimetics for cancer therapy[J]. Front Pharmacol,2018,9:1116.
[27]	LIMONI S K,MOGHADAM M F,MOAZZENI S M,et al.Engineered exosomes for targeted transfer of siRNA to HER2 positive breast cancer cells[J]. Appl Biochem Biotechnol,2019,187(1):352-364.
[28]	ALVAREZ-ERVITI L,SEOW Y,YIN H,et al.Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes[J]. Nat Biotechnol,2011,29(4):341-345.
[29]	LIANG G,ZHU Y,ALI D J,et al.Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer[J]. J Nanobiotechnology,2020,18(1):10.
[30]	YU M,GAI C,LI Z,et al.Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells[J]. Cancer Sci,2019,110(10):3173-3182.
[31]	XIONG F,LING X,CHEN X,et al.Pursuing specific chemotherapy of orthotopic breast cancer with lung metastasis from docking nanoparticles driven by bioinspired exosomes[J]. Nano Lett,2019,19(5):3256-3266.
[32]	LI S,WU Y,DING F,et al.Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer[J]. Nanoscale,2020,12(19):10854-10862.
[33]	ZUO B,QI H,LU Z,et al.Alarmin-painted exosomes elicit persistent antitumor immunity in large established tumors in mice[J]. Nat Commun,2020,11(1):1790.
[34]	GAO X,RAN N,DONG X,et al. Anchor peptide captures,targets,and loads exosomes of diverse origins for diagnostics and therapy[J]. Sci Transl Med,2018,10(444):eaat0195.
[35]	SHI X,CHENG Q,HOU T,et al.Genetically engineered cell-derived nanoparticles for targeted breast cancer immunotherapy[J]. Mol Ther,2020,28(2):536-547.

外泌体在乳腺癌诊治中的研究进展

The Progress of Exosomes Application in Diagnosis and Treatmeat of breast cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 35

相关文章 15

编辑推荐

Metrics

[1]	王蓉, 邢连翔, 黄克亮, 李欣. miR-374靶向下调TRIM35表达可促进乳腺癌细胞增殖和侵袭[J]. 检验医学, 2023, 38(9): 812-817.
[2]	陈文举, 周勇, 徐佳佳, 王攀. 血清外泌体miR-23b-3p和miR-4429诊断HCC的价值[J]. 检验医学, 2023, 38(7): 624-628.
[3]	潘信, 吕颖, 李阳, 李荣国. miR-24-3p靶向CHD5影响甲状腺癌细胞迁移能力、侵袭能力和放射敏感性[J]. 检验医学, 2023, 38(7): 640-646.
[4]	王腾飞, 陈珊, 安和兵, 周蕾. 急性白血病患者外周血lncRNA CRNDE、miR-384表达及其临床意义[J]. 检验医学, 2023, 38(7): 686-691.
[5]	张莹, 景丽娟, 李丽. HBV携带者外周血单个核细胞miR-138表达与病毒增殖的关系[J]. 检验医学, 2023, 38(6): 559-562.
[6]	陈琛, 段奇, 陆佳团, 翟晓建, 王征, 张浩, 郭满. 三阴性乳腺癌患者ASH2L、HOXA2表达及其与淋巴转移的关系[J]. 检验医学, 2023, 38(6): 574-578.
[7]	张敏, 王彬宇, 迟伟群, 刘禹. 外泌体非编码RNA作为疾病诊断生物标志物的研究进展[J]. 检验医学, 2023, 38(6): 594-598.
[8]	赵婧, 王佩, 卢丹丹, 齐丹丹, 李轩. 出血性脑卒中患者血清miR-4443、TRAF4相对表达量变化的临床意义[J]. 检验医学, 2023, 38(5): 413-418.
[9]	张国良, 刘鷖雯, 何怡青, 许静, 杨翠霞, 高锋, 刘华. 乳腺癌患者血清HAS2、CD44水平变化及其临床意义[J]. 检验医学, 2023, 38(5): 424-429.
[10]	刘瑞丽, 李兰军, 贾旻蕾, 王一惠, 郝维纳. 胃癌组织miR-7-5p、NOVA2表达与患者临床预后的相关性[J]. 检验医学, 2023, 38(4): 325-329.
[11]	袁爽, 冯磊, 郭小芬, 付小玲, 许静, 刘弘扬. 子宫内膜癌组织miR-433的表达及其与化疗敏感性的关系[J]. 检验医学, 2023, 38(4): 337-341.
[12]	李牧, 龚东亮, 徐黎明, 彭荣. XPC rs2228000位点多态性与乳腺癌发病的关系[J]. 检验医学, 2023, 38(3): 235-239.
[13]	陈哲, 张灵, 刘洁, 王霞, 张斌, 高炳华. 血清miR-326与治疗相关性血液系统恶性肿瘤患者化疗敏感性和预后的关系[J]. 检验医学, 2023, 38(3): 251-256.
[14]	刘冲, 张静, 李胜, 赵奇. miR-335和Fra-1在乳腺癌中的表达及相互关系[J]. 检验医学, 2023, 38(2): 143-147.
[15]	吴炯, 胡嘉华, 施美芳, 刘涛, 戴洁, 卢忻怡, 邹政. 前列腺癌生物标志物研究进展[J]. 检验医学, 2023, 38(2): 190-195.